0001375151-20-000004.txt : 20200110
0001375151-20-000004.hdr.sgml : 20200110
20200110161519
ACCESSION NUMBER: 0001375151-20-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200108
FILED AS OF DATE: 20200110
DATE AS OF CHANGE: 20200110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FARR STEPHEN J
CENTRAL INDEX KEY: 0001247666
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34962
FILM NUMBER: 20521222
MAIL ADDRESS:
STREET 1: SFARR@ZOGENIX.COM
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZOGENIX, INC.
CENTRAL INDEX KEY: 0001375151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205300780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 500
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: (510) 550-8300
MAIL ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 500
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: ZOGENIX INC
DATE OF NAME CHANGE: 20060911
4
1
wf-form4_157869090162160.xml
FORM 4
X0306
4
2020-01-08
0
0001375151
ZOGENIX, INC.
ZGNX
0001247666
FARR STEPHEN J
C/O ZOGENIX, INC.
5959 HORTON STREET, SUITE 500
EMERYVILLE
CA
94608
1
1
0
0
President and CEO
Common Stock
2020-01-08
4
M
0
29559
10.35
A
86267
D
Common Stock
2020-01-08
4
M
0
4666
10.64
A
90933
D
Common Stock
2020-01-08
4
S
0
28955
51.8327
D
61978
D
Common Stock
2020-01-08
4
S
0
5270
52.2021
D
56708
D
Stock Option (Right to Buy)
10.35
2020-01-08
4
M
0
29559
0
D
2026-03-13
Common Stock
29559.0
100428
D
Stock Option (Right to Buy)
10.64
2020-01-08
4
M
0
4666
0
D
2025-03-17
Common Stock
4666.0
26583
D
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
Includes 181 shares acquired under the Company's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.28 to $51.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.54, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option was granted on March 14, 2016 and vests in a series of forty-eight (48) successive, equal monthly installments measured from the date of grant, subject to the Reporting Person's continuous service to the Company on each vesting date.
The Option was granted on March 17, 2015 and vests in a series of forty-eight (48) successive, equal monthly installments measured from the date of grant, subject to the Reporting Person's continued service to the Company on each vesting date.
/s/ Thomas Doyle, Attorney-in-fact for Stephen Farr
2020-01-10